Genomic testing in patients with early-stage breast cancer is associated with decreased use of chemotherapy and lower costs in younger patients, and slightly increased use of chemotherapy and higher costs in older patients. Genomic testing in actual practice may “rule out” chemotherapy in younger women, and “rule in” chemotherapy in older women
Background: Genomic recurrence risk test results now inform clinical decisions about adjuvant treatm...
We sought to examine how patients’ treatment decisions incorporate potentially conflicting informati...
AbstractObjectiveOncotype DX, a 21-gene assay, was clinically validated as a predictor of 10-year re...
Genomic testing in patients with early-stage breast cancer is associated with decreased use of chemo...
Practice guidelines incorporate genomic tumor profiling, using results such as the Oncotype DX Recur...
Introduction. Advances in genomic techniques have been valuable in guiding decisions regarding the t...
Thesis (Ph. D.)--University of Washington, 2004In the U.S., the majority of premenopausal breast can...
Abstract Background Genomic tests are a useful tool for adjuvant chemotherapy decision‐making in the...
Objectives: The 21-Gene Recurrence Score (RS) assay helps guide adjuvant chemotherapy use for patien...
Introduction: The decision to initiate adjuvant chemotherapy after surgery in patients with estrogen...
PURPOSE: Given the likely proliferation of targeted testing and treatment strategies for cancer, a b...
International audienceThe use of taxanes to treat node-positive (N+) breast cancer patients is assoc...
Purpose: We assessed the recent trends in the administration of adjuvant chemotherapy thereby evalua...
As gene expression profile (GEP) testing for breast cancer may provide additional prognostic informa...
Background: Oncotype DX testing has reduced the use of adjuvant chemotherapy in node-negative early ...
Background: Genomic recurrence risk test results now inform clinical decisions about adjuvant treatm...
We sought to examine how patients’ treatment decisions incorporate potentially conflicting informati...
AbstractObjectiveOncotype DX, a 21-gene assay, was clinically validated as a predictor of 10-year re...
Genomic testing in patients with early-stage breast cancer is associated with decreased use of chemo...
Practice guidelines incorporate genomic tumor profiling, using results such as the Oncotype DX Recur...
Introduction. Advances in genomic techniques have been valuable in guiding decisions regarding the t...
Thesis (Ph. D.)--University of Washington, 2004In the U.S., the majority of premenopausal breast can...
Abstract Background Genomic tests are a useful tool for adjuvant chemotherapy decision‐making in the...
Objectives: The 21-Gene Recurrence Score (RS) assay helps guide adjuvant chemotherapy use for patien...
Introduction: The decision to initiate adjuvant chemotherapy after surgery in patients with estrogen...
PURPOSE: Given the likely proliferation of targeted testing and treatment strategies for cancer, a b...
International audienceThe use of taxanes to treat node-positive (N+) breast cancer patients is assoc...
Purpose: We assessed the recent trends in the administration of adjuvant chemotherapy thereby evalua...
As gene expression profile (GEP) testing for breast cancer may provide additional prognostic informa...
Background: Oncotype DX testing has reduced the use of adjuvant chemotherapy in node-negative early ...
Background: Genomic recurrence risk test results now inform clinical decisions about adjuvant treatm...
We sought to examine how patients’ treatment decisions incorporate potentially conflicting informati...
AbstractObjectiveOncotype DX, a 21-gene assay, was clinically validated as a predictor of 10-year re...